{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:56:14Z","timestamp":1777564574560,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.lungcan.2016.06.020","type":"journal-article","created":{"date-parts":[[2016,7,2]],"date-time":"2016-07-02T16:28:08Z","timestamp":1467476888000},"page":"111-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience"],"prefix":"10.1016","volume":"99","author":[{"given":"M.V.","family":"Bluthgen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Boutros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Fayard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Remon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Planchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Besse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2016.06.020_bib0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00277-002-0597-6","article-title":"Malignant thymoma: current status of classification and multimodality treatment","volume":"82","author":"Schmidt-Wolf","year":"2003","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0010","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","article-title":"The 2015 world health organization classification of tumors of the thymus: continuity and changes","volume":"10","author":"Marx","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0015","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ijrobp.2003.11.021","article-title":"Thymic carcinoma: state of the art review","volume":"59","author":"Eng","year":"2004","journal-title":"Int. J. Radiat. Oncol."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0020","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/path.1514","article-title":"KIT(CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas","volume":"202","author":"Pan","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0025","doi-asserted-by":"crossref","first-page":"S1698","DOI":"10.1097\/JTO.0b013e31821e7b12","article-title":"A review of prognostic factors in thymic malignancies","volume":"6","author":"Detterbeck","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0030","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/JTO.0000000000000215","article-title":"others Prognostic factors for cure, recurrence and long-term survival after surgical resection of thymoma","volume":"9","author":"Safieddine","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0035","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.athoracsur.2003.10.001","article-title":"Thymic tumors","volume":"77","author":"Detterbeck","year":"2004","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0040","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.1990.8.8.1419","article-title":"Chemotherapy of invasive thymoma","volume":"8","author":"Fornasiero","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0045","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4","article-title":"Chemotherapy for invasive thymoma. a 13-year experience","volume":"68","author":"Fornasiero","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2016.06.020_bib0050","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0055","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0060","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"for the West Japan Oncology Group, A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0065","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/JTO.0b013e3181db3dee","article-title":"Combined etoposide ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience","volume":"5","author":"Grassin","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0070","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma","volume":"91","author":"Loehrer","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2016.06.020_bib0075","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0080","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2217\/fon.14.144","article-title":"Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial","volume":"10","author":"Palmieri","year":"2014","journal-title":"Future Oncol."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0085","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lungcan.2014.11.006","article-title":"Pemetrexed in patients with thymic malignancies previously treated with chemotherapy","volume":"87","author":"Liang","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.06.020_bib0090","article-title":"A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma","volume":"24","author":"Loehrer","year":"2006","journal-title":"J. Clin. Oncol. Meet. Abstr."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0095","first-page":"1","article-title":"Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations","author":"Okuma","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0100","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","article-title":"Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an eastern cooperative oncology group phase II trial","volume":"22","author":"Loehrer","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0105","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/COC.0b013e318209a8f8","article-title":"Efficacy and tolerability of long-acting octreotide in the treatment of thymic tumors: results of a pilot trial","volume":"35","author":"Longo","year":"2012","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"others, Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"issue":"suppl","key":"10.1016\/j.lungcan.2016.06.020_bib0115","article-title":"Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"32:5s","author":"Zucali","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0120","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.1996.14.3.814","article-title":"Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"14","author":"Giaccone","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0125","doi-asserted-by":"crossref","first-page":"454","DOI":"10.4103\/0019-509X.92279","article-title":"Carboplatin plus etoposide for extensive stage small-cell lung cancer: an experience with AUC 6 doses of carboplatin","volume":"48","author":"Yilmaz","year":"2011","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.lungcan.2016.06.020_bib0130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejcts.2009.05.038","article-title":"Thymoma and thymic carcinoma","volume":"37","author":"Venuta","year":"2010","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0135","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.bjc.6605731","article-title":"A phase II trial of dose-dense chemotherapy, followed by surgical resection and\/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606)","volume":"103","author":"Kunitoh","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"suppl","key":"10.1016\/j.lungcan.2016.06.020_bib0140","article-title":"Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM)","volume":"33","author":"Wakelee","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.06.020_bib0145","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors","volume":"29","author":"Giaccone","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"suppl","key":"10.1016\/j.lungcan.2016.06.020_bib0150","article-title":"A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC)","author":"Besse","year":"2014","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216303786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216303786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T12:16:49Z","timestamp":1568117809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500216303786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":30,"alternative-id":["S0169500216303786"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.06.020","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}